Sun Hongxia, Chen Hui, Crespo James, Tang Guilin, Robinson Melissa, Lim Bora, Şahin Ayşegül A
Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Eur J Breast Health. 2021 Mar 31;17(2):128-136. doi: 10.4274/ejbh.galenos.2021.2021-2-9. eCollection 2021 Apr.
The interpretation of human epidermal growth factor receptor 2 () fluorescence in situ hybridization (FISH) results may be challenging in tumors with polysomy 17, which is defined as increased signals of chromosome enumeration probe 17 (CEP17). The effect of polysomy 17 on protein expression and tumor treatment response has not been established. In this retrospective study, we investigated the clinicopathological features of breast cancer with polysomy 17 and determined the tumors' response to neoadjuvant chemotherapy (NACT).
The study included 366 patients with primary breast cancer whose tumors had a CEP17 count of ≥ three/nucleus based on FISH studies. These cases were categorized according to /CEP17 ratio and signals/nucleus using the American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines. We compared the clinicopathological characteristics and tumor response to NACT among different groups.
There was a statistically significant difference in patients' age at diagnosis, tumor pathological grade, estrogen and progesterone receptor status, and NACT response among different FISH groups. Polysomy 17 tumors in group 1 had a higher rate of response (pathological complete response and residual cancer burden class I) to NACT containing anti- reagent than did those in other groups (p = 0.004), whereas polysomy 17 tumors in group 3 did not show a significant response to anti- treatment.
Polysomy 17 tumors in different FISH groups have different pathological features and respond to NACT differently. These results may help us identify patients who will benefit from anti- therapy.
在具有17号染色体多体性（定义为染色体计数探针17（CEP17）信号增加）的肿瘤中，人表皮生长因子受体2（HER2）荧光原位杂交（FISH）结果的解读可能具有挑战性。17号染色体多体性对HER2蛋白表达和肿瘤治疗反应的影响尚未明确。在这项回顾性研究中，我们调查了具有17号染色体多体性的乳腺癌的临床病理特征，并确定了肿瘤对新辅助化疗（NACT）的反应。
该研究纳入了366例原发性乳腺癌患者，其肿瘤基于FISH研究的CEP17计数≥3/核。根据美国临床肿瘤学会/美国病理学家学会（ASCO/CAP）指南，这些病例根据HER2/CEP17比率和HER2信号/核进行分类。我们比较了不同组之间的临床病理特征和肿瘤对NACT的反应。
不同FISH组在患者诊断时的年龄、肿瘤病理分级、雌激素和孕激素受体状态以及NACT反应方面存在统计学显著差异。与其他组相比，第1组中具有17号染色体多体性的肿瘤对含抗HER2试剂的NACT的反应率（病理完全缓解和残余癌负担I级）更高（p = 0.004），而第3组中具有17号染色体多体性的肿瘤对抗HER2治疗未显示出显著反应。
不同FISH组中具有17号染色体多体性的肿瘤具有不同的病理特征，对NACT的反应也不同。这些结果可能有助于我们识别将从抗HER2治疗中获益的患者。
